Small Molecules for Cancer or Autoimmunity Icon

Cambridge Healthtech Institute’s 3rd Annual

Small Molecules for Cancer or Autoimmunity

April 19-20, 2022

 

Discovery and design of small molecule-based oncology and immunomodulating therapies (activators for cancer or suppressors for autoimmunity), expands therapeutic avenues because small molecules can enter cells thereby reaching a wider array of disease-causing complexes. The greater patient convenience afforded by the oral bioavailability potential of small molecule-based treatments also adds to their value. Yet most small molecule or oral-based medicines on the market for cancer are older, non-specific chemotherapy drugs. Join fellow medicinal chemists at Cambridge Healthtech Institute's 3rd Annual Small Molecules for Cancer or Autoimmunity conference to share progress and approaches in the burgeoning field of targeted small molecule cancer and immunomodulating therapies. 

 

Coverage will likely include:

 

  • Tackling ‘difficult’ intracellular cancer and/or autoimmune targets (KRAS, STING, NLRP3, BCL complexes and more) with small molecules
  • Small molecule T cell checkpoint inhibitors
  • Checkpoint inhibitors of macrophage targets
  • New synthetic lethality cancer discovery approaches
  • Remodeling the tumor microenvironment (TME) with small molecules
  • A2AR antagonists and other GPCR small molecule modulators for immuno-oncology

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is October 1, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

We hope you can join us for this and the 4 concurrent day-and-a-half conferences during the first half of our 17th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda, whether you join in person or virtually.

 

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For partnering and sponsorship information, please contact:

Aimee Croke
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5458
Email: acroke@cambridgeinnovationinstitute.com